Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0461929603
Wed, 31.03.2021
Xlife Sciences AG
Xlife Sciences AG (XLS): 2020 financial results
Xlife increases net profit to 21.2 million Swiss francs
In 2020, Xlife Sciences AG (XLS) significantly increased its profit to 21.2 million Swiss francs compared to the previous year (1.03 million). The increase is based on the transaction and the capital appreciation of the portfolio companies Vela [ … ]
Fri, 08.01.2021
Xlife Sciences AG
Xlife Sciences AG: Transaction with Baliopharm AG
License Deal of 300 million euros successfully completed Xlife Sciences AG has reached a licensing agreement with the biotech firm Baliopharm AG, located in Basel. According to the agreement, Xlife Sciences AG will receive 10% of future income from license fees of Baliopharm AG. The Basel-based com [ … ]
Wed, 23.12.2020
Xlife Sciences AG
Xlife Sciences AG: Exit of a project company
More than 20 million euros transaction completed
Xlife Sciences AG has successfully realized its 60% stake of the project company Araxa Biosciences GmbH in Veraxa Biotech AG (formerly Velaxa AG). This transaction has a total value of more than 20 million euros and Xlife Sciences AG will now become a pa [ … ]
Wed, 05.08.2020
Xlife Sciences AG
Xlife Sciences AG (XLS DE, Xetra) acquires a 50% stake in palleos healthcare GmbH, Wiesbaden, Germany. Based on an approximate valuation of the company at EUR 10.0 million, the acquisition price is EUR 4.0 million and 40,000 shares of Xlife Sciences AG. Specific milestones have been agreed upon for the final settlement date and acquisition price, s [ … ]